Campbell, Matthew T. http://orcid.org/0000-0003-1915-4491
Matin, Surena F. http://orcid.org/0000-0003-1638-1445
Tam, Alda L.
Sheth, Rahul A. http://orcid.org/0000-0001-9615-8985
Ahrar, Kamran
Tidwell, Rebecca S. http://orcid.org/0000-0003-3041-8582
Rao, Priya
Karam, Jose A. http://orcid.org/0000-0001-7697-9591
Wood, Christopher G.
Tannir, Nizar M.
Jonasch, Eric http://orcid.org/0000-0003-0943-2806
Gao, Jianjun http://orcid.org/0000-0001-6138-4472
Zurita, Amado J.
Shah, Amishi Y. http://orcid.org/0000-0002-9007-0621
Jindal, Sonali
Duan, Fei
Basu, Sreyashi http://orcid.org/0000-0002-5028-3833
Chen, Hong
Espejo, Alexsandra B. http://orcid.org/0000-0002-8841-7219
Allison, James P.
Yadav, Shalini S.
Sharma, Padmanee http://orcid.org/0000-0003-4658-055X
Funding for this research was provided by:
Conquer Cancer Foundation
MedImmune
AstraZeneca
Article History
Received: 5 May 2021
Accepted: 5 October 2021
First Online: 4 November 2021
Competing interests
: M.T.C. reports consulting/advisory roles for AstraZeneca, Astellas, Eisai, EMD Serono, Exelixis, Genentech, Pfizer, Seattle Genetics, Consulting: AXDev, Exelixis, Pfizer, Research grants: ApricityHealth, EMD Serono, Exelixis, Janssen, Pfizer, Non-CME education: Bristol Myers-Squibb, Merck, Roche, Pfizer. S.F.M. reports consulting/advisory roles for Johnson and Johnson and Research Funding from QED; Education—Ology education. A.L.T. reports consulting/advisory roles for Boston Scientific, Cello Therapeutics, Endocare, AstraZeneca; and Research Funding from Boston Scientific, Johnson & Johnson. R.A.S. reports consulting/advisory roles for Varian, Boston Scientific. J.A.K. reports consulting/advisory roles for Pfizer, Merck, Roche/Genentech, and Research Funding from Roche/Genentech, Mirati, Merck, Elypta; Stock Ownership: Allogene, MedTek, ROM Technologies. N.M.T. reports consulting/advisory roles for Bristol Myers-Squibb; Pfizer; Nektar Therapeutics; Exelisis, Inc, Eisai Medical Research; Eli Lilly; Oncorena; Calithera Bioscience; Surface Oncology; Novartis, Ipsen; Merck Sharp & Dohme and Research Funding from Bristol Myers-Squibb; Nektar Therapeutics; Calithera Bioscience; Arrowhead Pharmaceuticals, Inc. E.J. reports consulting/advisory roles for Eisai, Exelixis, Novartis, Merck, Pfizer, Roche. And Research support from Exelixis, Merck, Pfizer. J.G. reports consulting/advisory roles for Seattle Genetics, Jounce Therapeutics, Pfizer, Janssen, Symphogen, AstraZeneca, ARMO biosciences, CRISPR Therapeutics AG. A.J.Z. reports consulting/advisory roles for AstraZeneca and Bayer and Research funding to his institution from Infinity Pharma, Honoraria from Pfizer, and Janssen. A.Y.S. reports consulting/advisory roles for Ad boards, Pfizer, Exelixis, and Research Grant funding from Bristol Myers-Squibb, Eisai, EMD Serono. J.P.A. reports consulting, advisory roles, and/or stocks/ownership for Achelois, Apricity Health, BioAtla, Codiak BioSciences, Dragonfly Therapeutics, Forty-Seven Inc., Hummingbird, ImaginAb, Jounce Therapeutics, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, Polaris, BioNTech, and Adaptive Biotechnologies; and owns a patent licensed to Jounce (61/247,438; “Combination Immunotherapy for the Treatment of Cancer”). P.S. reports consulting, advisory roles, and/or stocks/ownership for Achelois, Apricity Health, BioAlta, Codiak BioSciences, Constellation, Dragonfly Therapeutics, Forty-Seven Inc., Hummingbird, ImaginAb, Jounce Therapeutics, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, Oncolytics, Infinity Pharma, BioNTech, Adaptive Biotechnologies, and Polaris; and owns a patent licensed to Jounce Therapeutics (61/247,438; “Combination Immunotherapy for the Treatment of Cancer”). The remaining authors declare no potential competing interest.